English
Home > Products > CAS:57-83-0

China CAS:57-83-0 Manufacturer

We are commitment to offer the competitive price ,outstanding products quality, as well as fast delivery for CAS:57-83-0, With our rules of " small business track record, partner trust and mutual benefit", welcome all of you to definitely work together , expand with each other.
CAS:57-83-0, Our aim is to help customers realize their goals. We have been making great efforts to achieve this win-win situation and sincerely welcome you to join us. In a word, when you choose us, you choose a perfect life. Welcome to visit our factory and welcome your order! For further inquiries, remember to do not hesitate to contact us.

Related Products

Hot Products

  • Methylprednisolone Hemisuccinate

    Methylprednisolone Hemisuccinate

    For Methylprednisolone Hemisuccinate, we have EP, USP and CP specification. DMF and WC available.

    CAS:2921-57-5

  • Cyproterone Acetate

    Cyproterone Acetate

    For Cyproterone Acetate (CPA), we have CP and EP specifications, CEP/TGA/EU-GMP available.

    CAS:427-51-0

  • Abiraterone Acetate

    Abiraterone Acetate

    Abiraterone Acetate has CP,USP specifications. DMF, WC available.

    CAS:154229-18-2

  • Testosterone

    Testosterone

    Testosterone has CP,EP and USP specifications. CEP, DMF, WC, FDA available..

    CAS:58-22-0

  • Dienogest

    Dienogest

    Dienogest has EP specifications. DMF approved.

    CAS:65928-58-7

  • Cyproterone Acetate Tablets

    Cyproterone Acetate Tablets

    Cyproterone Acetate Tablets Specifications：50mg*24
    Indications：Anti-androgen
  • Related Blog
  • Reviews

  • 2022 CPhI Exhibition Shanghai

    CPhI is the undisputed leader in the pharmaceutical industry. CPhI China offers a key access point to the second largest pharma market in the world. The exhibition features over 3,000 companies and incorporates various API showcases like bioLIVE, iCSE, NEX and FDF, creating a comprehensive platform that connects the entire pharmaceutical industry chain in the Asian-Pacific region.

  • 2023 See us at DCAT Week, CPHI and API exhibition!

  • 2024 Exhibition Calendar: Connect with Us and Explore New Possibilities!

    Our 2024 Exhibition Calendar has been announced! Come meet our team and explore new business opportunities.We look forward to seeing you there!

  • CPHI & PMEC China 2024 Ended Successfully

    From June 19 to 21, the 22nd World Pharmaceutical Raw Materials China Exhibition (CPHI China 2024), organized by Informa Markets and China Chamber of Commerce for Import and Export of Pharmaceutical and Health Products and co-organized by Shanghai Bohua International Exhibition Co., LTD., was held in Shanghai. Nearly 3,500 well-known exhibitors at home and abroad gathered in Shanghai New International Expo Center (Pudong), attracting more than 60,000 professional buyers from more than 150 countries and regions, and a total of more than 90,000 industry colleagues to participate in the event.

  • What are the categories of pharmaceutical intermediates?

    Pharmaceutical intermediates are classified by therapeutic areas, chemical structures, synthesis stages and production technologies, covering multiple types such as anti-tumor and anti-infection. They are key precursors in the synthesis of active pharmaceutical ingredients.

  • What Is Epiandrosterone and Why Is It Becoming Popular in Modern Hormone Research

    In recent years, Epiandrosterone has gained increasing attention in biochemical research, pharmaceutical development, and hormone metabolism studies. As a naturally occurring androgen metabolite, this compound plays an important role in steroid biosynthesis and endocrine pathways. Scientists and manufacturers are exploring its potential applications in hormone research, biochemical analysis, and advanced pharmaceutical intermediates.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept